Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Glaston publishes the January 1–March 31, 2019 Interim Report on Monday, April 29, 2019 at 13.00

Glaston Corporation           Press release          23.4.2019 at 10.00Glaston Corporation will publish its January-March 2019 Interim Report on Monday, 29 April, 2019 at 13.00 p.m.The Interim Report will be available after publishing on the Company’s internet pages at www.glaston.net.The analyst and press conference hosted at Glaston’s office on Lönnrotinkatu 11, Helsinki, will be on the same day at 14.30 p.m. The report will be presented by Glaston’s CEO and President Arto Metsänen and CFO Päivi Lindqvist. GLASTON CORPORATIONJoséphine MickwitzVP, IR, Communications and

Chairman Klas Cramborn has passed away after a period of illness

By reason of chairman Klas Cramborn's death, the Board of Directors of Phase Holographic Imaging (PHI) has decided to appoint Mats Lundwall as acting chairman of the Board.“Klas has meant a lot to PHI’s development. With his strategic skills in combination integrity and humor Klas has led the Board in a very commendable way since 2010. Klas was highly regarded by both fellow board members and employees. He will be greatly missed”, says Mats Lundwall. Mats Lundwall, former CEO of Cellartis, Santaris Pharma, Ferring Pharmaceuticals and Euro Diagnostica, has been a member of the Board since

INVITATION TO PRESENTATION OF FIRST QUARTER 2019 FINANCIAL RESULTS

Oslo, Norway (23 April 2019) — NattoPharma will release its first quarter financial results on Tuesday 30th April 2019 at approximately 08:00 CET. The report will be made available at www.nattopharma.com and at www.oslobors.no. The same day, starting at 10:00 am, the company will host a webcast with a presentation of the results, followed by an online Q&A session. Please follow the below link to join the web-cast, https://webtv.hegnar.no/presentation.php?webcastId=97815185 For more information, please contact: Kjetil Ramsøy CEO, NattoPharma E-mail: kjetil.ramsoy@

Agreement for negotiation and sale for VAL001

Respiratorius has signed an agreement with Partner International Inc. to complete the exit of VAL001. The assignment for Partner International is to work with already identified candidates as well as seek additional stakeholders to reach an agreement as soon as possible.Since the start of the VAL001 exit process, the clinical study has been completed with strong results and we have received additional patent approvals that give a excellent patent position with approved patents in Europe, the USA, Japan and Korea. Furthermore, the European Medicines Agency (EMA) has, in scientific advice,

Net Gaming publishes Annual Report for 2018

Net Gaming Europe has today published its Annual Report for 2018 on the Company’s website, www.netgaming.se. The report is available in both Swedish and English.While preparing the 2018 Annual Report, Net Gaming noted, after publication of the 2018 Year-end Report, that goodwill of EUR 39 million had been recorded at the historical cost of SEK 370 million. A goodwill adjusted of SEK 31.2 million has therefore been recognized, which has improved the Company’s equity by the corresponding amount. Detailed information is provided in Note 20 of the Annual Report. For further information,

Notice to Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)

This is an unofficial translation of a notice to the Annual General Meeting in ExpreS2ion Biotech Holding AB, originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail. The shareholders of ExpreS2ion Biotech Holding AB (publ), 559033-3729, are hereby invited to attend the Annual General Meeting on Thursday, May 23, 2019 at 16.00 at Mazars SET's office, Terminalgatan 1, in Helsingborg.Right to participate and registration Shareholders who wish to attend the Annual General Meeting shall · be

Asarina Pharma Clinical Trial featured on BBC

(Stockholm April 23 2019) With approx. 4 million listeners, on April 17 BBC Radio’s iconic programme ‘Woman’s Hour’ highlighted the clinical trial of a new treatment for PMDD, the severest form of PMS. The trial is being carried out by Swedish company Asarina Pharma“Why is PMDD so difficult to treat, and what help might a new trial offer to those who suffer?” Founded in 1946, ‘Woman’s Hour’ is followed by millions of loyal listeners. On April 17 the program ran a 10-minute feature on PMDD, the severest, devastating form of PMS, and a new trial being held into the first treatment ever to

Pharmacolog moves to new premises

Pharmacolog have moved and is now situated in new, renovated premises in Ekeby bruk, Uppsala, entrance 2H since April 10th. In order to manage the increasing number of employees, the company needed access to larger premises.The former office premises, where the company has been operating since 2014, were too small to be able to accommodate the increasing number of employees. The company has therefore moved to larger and more suitable premises in the same property in Ekeby Bruk, Uppsala. The company currently engages 9-10 people full time in the business, which will increase in the near

Interim report January – March 2019: High profitability and new business unit

First quarter:· Sales amounted to SEK 312 (264) million, corresponding to an increase of 18 percent in SEK. Sales increased by 12 percent in local currency whereof 4 percent comprised organic growth.· Operating income before depreciation and amortisation (EBITDA) amounted to SEK 126 (106) million, corresponding to a margin of 40 (40) percent. Fluctuations in exchange rates positively impacted EBITDA by SEK 14 million.· Net income amounted to SEK 86 (72) million, which gave earnings per share of SEK 0.79 (0.66).· Market approval for EmbryoScope+ in China. After the end of the

Epiroc awards recognize customer collaboration and autonomous drill rigs

Stockholm, Sweden: Epiroc’s first annual awards recognize close customer collaboration in Mongolia and innovative autonomous drill rigs in Australia.The United in Performance Award honors exceptional customer collaboration. This inaugural award is presented to Anders Berglund, Bayar Torguud, Batzorig Jamsranjav and Alf Lawrence at Epiroc’s Customer Center in Mongolia, as well as to mining company Oyu Tolgoi LLC. Their far-reaching collaboration is boosting productivity and safety at Oyu Tolgoi’s major copper mine. With the mine located remotely in the South Gobi desert, Epiroc has developed

Notice of Annual General Meeting of Net Gaming Europe AB (publ)

The shareholders of Net Gaming Europe AB (publ), 556693-7255, are hereby given notice of the Annual General Meeting at 1.00 p.m. on Thursday 23 May 2019 at Advokatfirma DLA Piper Sweden’s premises at Kungsgatan 9 in Stockholm.Notification of attendance etc.Shareholders wishing to attend the AGM must be registered in Euroclear AB’s share register as at Friday 17 May 2019, and must send written notification, no later than Monday 20 May 2019, to Net Gaming Europe AB (publ), Box 7385, 103 91 Stockholm, Sweden or by e-mail to info@netgaming.se. The notification must include the full name,

Metacon Expands Global Leadership Team

Metacon today announced the appointment of Marc Poppe as Senior Advisor, enhancing the Company’s global leadership capabilities. The appointment became effective April 22, 2019. Marc will mainly be based out of Tokyo and will focus on the Japanese market, but will also advise Metacon on global activities. A German national, Marc also speaks fluent Japanese and English. "I’m very pleased to have Marc joining our team. He brings deep professional knowledge, vast project management skills, legal background and cross-border collaborations. He will add valuable experience to our efforts in

Notice pursuant to the Finnish Securities Market Act, Chapter 9, Section 10 – BlackRock, Inc’s holding in Konecranes

KONECRANES PLC STOCK EXCHANGE RELEASE April 23, 2019 9:30 EETNotice pursuant to the Finnish Securities Market Act, Chapter 9, Section 10 – BlackRock, Inc’s holding in KonecranesKonecranes has on April 18, 2019, received a notification under Chapter 9, Section 5 of the Securities Market Act, according to which the holding of BlackRock, Inc. in Konecranes Plc’s shares and votes has fallen below 5 percent.On April 17, 2019, BlackRock, Inc.’s holding through shares amounted to 4.96 percent of Konecranes Plc’s shares and votes.Total positions of BlackRock, Inc.: % of

HIDDN – TACTILIS update

Reference is made to the earlier announced Letter of Intent (LOI) between Hiddn Solutions ASA (Hiddn) and Tactilis Pte Limited (Tactilis). Due to an earlier agreement that Tactilis had entered into before the announced LOI with Hiddn, Tactilis also had engaged into a process to merge their Malaysian daughter company with Global Invacom Group, a Singapore based listed company and through this merger, obtain listing on the Singapore Stock Exchange. Hiddn has been informed that the Tactilis process to merger their Malaysian daughter company with Global Invacom Group, has been mutually

New open-enrolment executive programmes now offered at School of Business, Economics and Law, University of Gothenburg

The School of Business, Economics and Law at the University of Gothenburg has announced it is now offering shorter, open-enrolment executive programmes as a complement to the school’s leading 21-month Executive MBA programme and 2-15-day Custom Programmes. The new Open-enrolment Programmes (OEPs) will primarily be 2 days long and are intended for executives and leaders who need to quickly develop their skills within a specific area.All OEP lecturers will be researchers who already teach on the Executive MBA programme or Custom Programmes. They are also experienced consultants within their

Interim report January-March 2019: The sixth quarter in row with improved results

· Strong organic growth and improved results · New orthopaedic clinic opened in Stockholm · Vårdsamverkan is investing in tools for analysing and optimising care chains · A postponement of revenue in International has negatively affected the quarter First quarter 2019 · Sales revenues increased to SEK 330.4 million (278.7) · Organic growth increased to 17.4 percent (10.7) · EBITDA increased to SEK 42.2 million (25.8). Excluding impact of IFRS 16, EBITDA increased to SEK 28.8 million (25.8) · EBITDA margin increased to 12.8 percent (9.3). Excluding impact of IFRS 16,

Hexagon CFO and EVP to act as CEO during periods of Ola Rollén’s unavailability due to court

Ola Rollén, Hexagon President and CEO, will appear in a court trial from 24 April to 29 May.To the extent that Ola Rollén is unavailable during the trial period, Hexagon CFO and EVP Robert Belkic will act as CEO.For further information, please contact:Daniel Johansson, Investor Relations, Hexagon AB, +46 8 601 26 27, ir@hexagon.comKristin Christensen , Chief Marketing Officer, Hexagon AB, +1 404 554 0972, media@hexagon.com

New Senior Vice President Operations

Daniel Lund with many years’ experience in quality, production and supply chain management from the pharmaceutical industry, including AstraZeneca and Pfizer, has been recruited to a new role as Senior Vice President (SVP) Operations. At the same time, Jonas Östregård assumes responsibility for Marketing. Both Daniel and Jonas are members of the management team and report to the CEO.“Daniel Lund has a broad and deep expertise in quality, logistics and supply chain management from the pharmaceutical industry. He has extensive experience in creating efficient processes and flows throughout

Statement regarding PPC advertising in Sweden

Raketech , a leading online affiliate and content marketing company, would like to clarify certain aspects and its position in regard to media reports and conclusions related to Google’s decision to allow advertising from gaming companies in Sweden.Google has informed Raketech that advertising for gambling will be allowed via so-called pay-per-click (PPC) advertising starting from April 29, via licensed gaming companies only. However, it is unclear if this is as a first step or a permanent decision. The decision to allow gambling operators to advertise on Google

Vicore Pharma announces systemic sclerosis as the second indication for VP01

Mölndal, April 23, 2019 - Vicore Pharma AB (publ) a leading rare diseases pharmaceutical company today announces that it has selected diffuse systemic sclerosis (dSSc) as the second indication for its lead program VP01 (C21),  which complements the primary indication, idiopathic pulmonary fibrosis (IPF). Diffuse systemic sclerosis is a disease with a strong involvement of angiotensin II and an upregulation of the angiotensin II type 2 receptor (AT2R - the C21 target), which is known to mediate anti-fibrotic as well as vascular effects within a number of disease models. VP01 is currently being

IRRAS Establishes Collaborative Relationship with AMI-USC Through Acquisition of Complementary Medical Device Technology

Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California (AMI-USC) is a World Class Biomedical Engineering Technology Development OrganizationStockholm, April 23, 2019 – IRRAS AB (Nasdaq First North Premier: IRRAS), a commercial-stage medical-technology company focused on developing and commercializing innovative solutions for intracranial bleeding pathologies, announced today it has entered into an agreement with the Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California (AMI-USC). Under the terms of the agreement,

Herantis Pharma Announces 12-Month Follow-Up Review from Phase 1 Lymfactin Trial in Breast Cancer-Associated Lymphedema

Herantis Pharma Announces 12-Month Follow-Up Review from Phase 1 Lymfactin® Trial in Breast Cancer-Associated Lymphedema Herantis Pharma PlcCompany release 23 April 2019 at 9:00 am Herantis Pharma Plc (“Herantis”) announced today the topline results from the 12-month follow-up review of the Phase 1 Lymfactin® trial in breast cancer-associated lymphedema. The study’s data monitoring committee (DMC) concluded that the treatment continues to be safe and well-tolerated in all patients with no severe adverse events. Lymfactin®, the novel gene therapy of Herantis that aims to repair the

Orkla ASA: Invitation to presentation of Orkla's first quarter 2019 results, Tuesday 7 May

Orkla will report its first quarter 2019 results on Tuesday, 7 May at 7.00 a.m. CET. The quarterly report and the presentation material will be available at this time at www.orkla.com.The quarterly results will be presented at 8.00 a.m. at the Orkla House, Drammensveien 149, Oslo. The presentation and subsequent Q&A session will be held in English and may be viewed in a live webcast at www.orkla.com or followed by telephone. Dial-in details: +47 21 03 33 94. Pincode: 1661193. To attend the presentation in Oslo, please register in advance by sending an email to: sara.freiman@orkla.no.

Share buy-backs in Telia Company during week 16 2019

During the period April 16, 2019, until April 18, 2019, Telia Company AB (publ) (LEI code 213800FSR9RNDUOTXO25) has repurchased in total 1,672,000 own shares (ISIN: SE0000667925). The share buy-backs form part of the SEK 5 billion share buy-back programme that Telia Company announced on April 16, 2019. The share buy-back programme, which runs between April 16, 2019, and February 28, 2020, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulation").During the period

There are no items matching the current filter
There are no more items matching the current filter
Back to top